The IMA, CDCM and CCT, seek to accelerate the development of promising and innovative early-stage translational stem cell and gene therapies that fill unmet clinical needs.
The Innovative Medicines Accelerator (IMA) aims to accelerate the translation of scientific discoveries at into new therapeutics that impact human health. This RFP supports treatments for spinal muscular atrophy and other neuromuscular diseases.
The Innovative Medicines Accelerator (IMA) aims to accelerate the prototyping of innovative medicines, and to enable hypothesis-driven studies on human subjects. This RFP seeks to leverage Stanford Clinical and Translational Research Unit.
The Innovative Medicines Accelerator (IMA) aims to accelerate the prototyping of innovative medicines, and to enable hypothesis-driven studies on human subjects. This RFP seeks to leverage Stanford infrastructure to address the COVID-19 pandemic
The Innovative Medicines Accelerator (IMA) aims to accelerate the prototyping of innovative medicines, and to enable hypothesis-driven studies on human subjects. This RFP seeks to leverage Stanford infrastructure to address the COVID-19 pandemic
Stanford ChEM-H is soliciting seed grant proposals from postdoc teams for exploratory projects that align with the Institute’s mission to bridge chemistry or engineering with biomedical sciences or medicine.
Stanford AIM is seeking target-driven drug discovery proposals with compelling therapeutic rationale, identified protein target amenable to therapeutic intervention, and sufficient evidence for a drug discovery effort from PI-eligible faculty.
